Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT01163357
Recruitment Status : Recruiting
First Posted : July 15, 2010
Last Update Posted : February 8, 2018
National Cancer Institute (NCI)
Information provided by (Responsible Party):
City of Hope Medical Center

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : September 2018
  Estimated Study Completion Date : September 2018